-
Information-Publications
-
Discovery of a highly potent NPAS3 heterodimer inhibitor by covalently modifying ARNTDetails
-
Additional mutations based on Omicron BA. 2.75 mediate its further evasion from broadly neutralizing antibodiesDetails
-
Circ_0087199 depletion attenuates lipopolysaccharides‐induced human periodontal ligament cell injury through the miR‐527/TLR4 axisDetails
-
D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunityDetails
-
Salvianolate ameliorates renal tubular injury through the Keap1/Nrf2/ARE pathway in mouse kidney ischemia-reperfusion injuryDetails
-
NSUN2 stimulates tumor progression via enhancing TIAM2 mRNA stability in pancreatic cancerDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands